Molecular mechanisms of atrial fibrosis: implications for the clinic

References

• Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–953.
   PubMed Web of Science ®Google Scholar
• Wong CX, Brooks AG, Lau DH, et al. Factors associated with the epidemic of hospitalizations due to atrial fibrillation. Am J Cardiol. 2012;110(10):1496–1499.
   PubMed Web of Science ®Google Scholar
• Wong CX, Brooks AG, Leong DP, et al. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. Arch Intern Med. 2012;172(9):739–741.
   PubMedGoogle Scholar
• Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92(7):1954–1968.
   PubMed Web of Science ®Google Scholar
• Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100(1):87–95.
   PubMed Web of Science ®Google Scholar
• Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49(5):565–571.
   PubMed Web of Science ®Google Scholar
• Lau DH, Middeldorp ME, Brooks AG, et al. Aortic stiffness in lone atrial fibrillation: a novel risk factor for arrhythmia recurrence. PLoS One. 2013;8(10):e76776.
   PubMed Web of Science ®Google Scholar
• Pathak RK, Elliott A, Middeldorp ME, et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol. 2015;66(9):985–996.
   PubMed Web of Science ®Google Scholar
• Tucker NR, Clauss S, Ellinor PT. Common variation in atrial fibrillation: navigating the path from genetic association to mechanism. Cardiovasc Res. 2016;109(4):493–501.
   PubMed Web of Science ®Google Scholar
• Rensma PL, Allessie MA, Lammers WJ, et al. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res. 1988;62(2):395–410.
   PubMed Web of Science ®Google Scholar
• Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91(1):265–325.
   PubMed Web of Science ®Google Scholar
• Heijman J, Voigt N, Nattel S, et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114(9):1483–1499.
   PubMed Web of Science ®Google Scholar
• Bukowska† A, Lendeckel† U, Hirte D, et al. Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. Cell Mol Life Sci CMLS. 2006;63(3):333–342.
   PubMed Web of Science ®Google Scholar
• Chelu MG, Sarma S, Sood S, et al. Calmodulin kinase II–mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest. 2009;119(7):1940–1951.
   PubMed Web of Science ®Google Scholar
• Choisy SCM, Arberry LA, Hancox JC, et al. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension. 2007;49(3):498–505.
   PubMed Web of Science ®Google Scholar
• Diness JG, Skibsbye L, Jespersen T, et al. Effects on atrial fibrillation in aged hypertensive rats by Ca2+-activated K+ channel inhibition. Hypertension. 2011;57(6):1129–1135.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Wang C, Miyauchi Y, et al. Aging-related increase to inducible atrial fibrillation in the rat model. J Cardiovasc Electrophysiol. 2002;13(8):801–808.
   PubMed Web of Science ®Google Scholar
• Kistler PM, Sanders P, Dodic M, et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J. 2006;27(24):3045–3056.
   PubMed Web of Science ®Google Scholar
• Lau DH, Mackenzie L, Kelly DJ, et al. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm. 2010;7(9):1282–1290.
   PubMed Web of Science ®Google Scholar
• Lau DH, Mackenzie L, Kelly DJ, et al. Short-term hypertension is associated with the development of atrial fibrillation substrate: a study in an ovine hypertensive model. Heart Rhythm. 2010;7(3):396–404.
   PubMed Web of Science ®Google Scholar
• Matsuyama N, Tsutsumi T, Kubota N, et al. Direct action of an angiotensin II receptor blocker on angiotensin II-induced left atrial conduction delay in spontaneously hypertensive rats. Hypertens Res. 2009;32(8):721–726.
   PubMed Web of Science ®Google Scholar
• Medi C, Kalman JM, Spence SJ, et al. Atrial electrical and structural changes associated with longstanding hypertension in humans: implications for the substrate for atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(12):1317–1324.
   PubMed Web of Science ®Google Scholar
• Gaspo R, Bosch RF, Talajic M, et al. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation. 1997;96(11):4027–4035.
   PubMed Web of Science ®Google Scholar
• Nattel S, Bourne G, Talajic M. Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation. J Cardiovasc Electrophysiol. 1997;8(4):469–480.
   PubMed Web of Science ®Google Scholar
• Abed HS, Samuel CS, Lau DH, et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm. 2013;10(1):90–100.
   PubMed Web of Science ®Google Scholar
• Dimitri H, Ng M, Brooks AG, et al. Atrial remodeling in obstructive sleep apnea: implications for atrial fibrillation. Heart Rhythm. 2012;9(3):321–327.
   PubMed Web of Science ®Google Scholar
• Iwasaki YK, Kato T, Xiong F, et al. Atrial fibrillation promotion with long-term repetitive obstructive sleep apnea in a rat model. J Am Coll Cardiol. 2014;64(19):2013–2023.
   PubMed Web of Science ®Google Scholar
• John B, Stiles MK, Kuklik P, et al. Electrical remodelling of the left and right atria due to rheumatic mitral stenosis. Eur Heart J. 2008;29(18):2234–2243.
   PubMed Web of Science ®Google Scholar
• Kato T, Yamashita T, Sekiguchi A, et al. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol. 2006;17(8):890–894.
   PubMed Web of Science ®Google Scholar
• Lau DH, Psaltis PJ, Mackenzie L, et al. Atrial remodeling in an ovine model of anthracycline-induced nonischemic cardiomyopathy: remodeling of the same sort. J Cardiovasc Electrophysiol. 2011;22(2):175–182.
   PubMed Web of Science ®Google Scholar
• Roberts-Thomson KC, John B, Worthley SG, et al. Left atrial remodeling in patients with atrial septal defects. Heart Rhythm. 2009;6(7):1000–1006.
   PubMed Web of Science ®Google Scholar
• Sanders P, Morton JB, Davidson NC, et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation. 2003;108(12):1461–1468.
   PubMed Web of Science ®Google Scholar
• Lau DH, Shipp NJ, Kelly DJ, et al. Atrial arrhythmia in ageing spontaneously hypertensive rats: unraveling the substrate in hypertension and ageing. PLoS One. 2013;8(8):e72416.
   PubMed Web of Science ®Google Scholar
• Platonov PG, Mitrofanova LB, Orshanskaya V, et al. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J Am Coll Cardiol. 2011;58(21):2225–2232.
   PubMed Web of Science ®Google Scholar
• Corradi D, Callegari S, Manotti L, et al. Persistent lone atrial fibrillation: clinicopathologic study of 19 cases. Heart Rhythm. 2014;11(7):1250–1258.
   PubMed Web of Science ®Google Scholar
• Stiles MK, John B, Wong CX, et al. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the “second factor”. J Am Coll Cardiol. 2009;53(14):1182–1191.
   PubMed Web of Science ®Google Scholar
• Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;18(10):1455–1490.
   PubMed Web of Science ®Google Scholar
• Kottkamp H. Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications. J Cardiovasc Electrophysiol. 2012;23(7):797–799.
   PubMed Web of Science ®Google Scholar
• Schotten U, Dobrev D, Platonov PG, et al. Current controversies in determining the main mechanisms of atrial fibrillation. J Intern Med. 2016;279(5):428–438.
   PubMed Web of Science ®Google Scholar
• Maesen B, Zeemering S, Afonso C, et al. Rearrangement of atrial bundle architecture and consequent changes in anisotropy of conduction constitute the 3-dimensional substrate for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6(5):967–975.
   PubMed Web of Science ®Google Scholar
• Nattel S, Dobrev D. Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. Nat Rev Cardiol. 2016;13(10):575–590.
   PubMed Web of Science ®Google Scholar
• Macrez N, Morel J-L, Kalkbrenner F, et al. A βγ dimer derived from G13 transduces the angiotensin AT1 receptor signal to stimulation of Ca2+ channels in rat portal vein myocytes. J Biol Chem. 1997;272(37):23180–23185.
   PubMed Web of Science ®Google Scholar
• Rattan S, Puri RN, Fan Y-P. Involvement of Rho and Rho-associated kinase in sphincteric smooth muscle contraction by angiotensin II. Exp Biol Med. 2003;228(8):972–981.
   Web of Science ®Google Scholar
• Ushio-Fukai M, Alexander RW, Akers M, et al. Angiotensin II receptor coupling to phospholipase D is mediated by the βγ subunits of heterotrimeric G proteins in vascular smooth muscle cells. Mol Pharmacol. 1999;55(1):142–149.
   PubMed Web of Science ®Google Scholar
• Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20(5):953–970.
   PubMed Web of Science ®Google Scholar
• Wang T-L, Yang Y-H, Chang H, et al. Angiotensin II signals mechanical stretch-induced cardiac matrix metalloproteinase expression via JAK-STAT pathway. J Mol Cell Cardiol. 2004;37(3):785–794.
   PubMed Web of Science ®Google Scholar
• Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802–809.
   PubMed Web of Science ®Google Scholar
• Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab. 2000;11(1):1–6.
   PubMed Web of Science ®Google Scholar
• Cao T, Gao Z, Gu L, et al. AdipoR1/APPL1 potentiates the protective effects of globular adiponectin on angiotensin II-induced cardiac hypertrophy and fibrosis in neonatal rat atrial myocytes and fibroblasts. PLoS One. 2014;9(8):e103793.
   PubMed Web of Science ®Google Scholar
• Kiryu M, Niwano S, Niwano H, et al. Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model. Europace. 2012;14(8):1206–1214.
   PubMed Web of Science ®Google Scholar
• McEwan PE, Gray GA, Sherry L, et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation. 1998;98(24):2765–2773.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Matsubara H, Ohkubo N, et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res. 1998;83(10):1035–1046.
   PubMed Web of Science ®Google Scholar
• Novo G, Guttilla D, Fazio G, et al. The role of the renin–angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol. 2008;66(3):345–351.
   PubMed Web of Science ®Google Scholar
• Rosenkranz S. TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63(3):423–432.
   PubMed Web of Science ®Google Scholar
• Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol. 2008;40(3):383–408.
   PubMed Web of Science ®Google Scholar
• Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003;113(6):685–700.
   PubMed Web of Science ®Google Scholar
• Kavsak P, Rasmussen RK, Causing CG, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation. Mol Cell. 2000;6(6):1365–1375.
   PubMed Web of Science ®Google Scholar
• Verheule S, Sato T, Everett T, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1. Circ Res. 2004;94(11):1458–1465.
   PubMed Web of Science ®Google Scholar
• Wilkes MC, Leof EB. Transforming growth factor β activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem. 2006;281(38):27846–27854.
   PubMed Web of Science ®Google Scholar
• Bujor AM, Asano Y, Haines P, et al. The C-ABL tyrosine kinase controls PKCδ induced Fli1 phosphorylation in human dermal fibroblasts. Arthritis Rheum. 2011;63(6):1729–1737.
   PubMed Web of Science ®Google Scholar
• Piera-Velazquez S, Li Z, Jimenez SA. Role of Endothelial-Mesenchymal Transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179(3):1074–1080.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Derynck R. Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition. Cells Tissues Organs. 2010;193(1–2):8–22.
   PubMed Web of Science ®Google Scholar
• Moustakas A, Heldin C-H. Non-Smad TGF-β signals. J Cell Sci. 2005;118(16):3573–3584.
   PubMed Web of Science ®Google Scholar
• Mu Y, Gudey S, Landström M. Non-Smad signaling pathways. Cell Tissue Res. 2012;347(1):11–20.
   PubMed Web of Science ®Google Scholar
• Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TGF-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res. 2007;67(8):3752–3758.
   PubMed Web of Science ®Google Scholar
• Pannu J, Nakerakanti S, Smith E, et al. Transforming growth factor-β receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem. 2007;282(14):10405–10413.
   PubMed Web of Science ®Google Scholar
• Mahajan R, Lau DH, Brooks AG, et al. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol. 2015;66(1):1–11.
   PubMed Web of Science ®Google Scholar
• Nakatani Y, Nishida K, Sakabe M, et al. Tranilast prevents atrial remodeling and development of atrial fibrillation in a canine model of atrial tachycardia and left ventricular dysfunction. J Am Coll Cardiol. 2013;61(5):582–588.
   PubMed Web of Science ®Google Scholar
• Thanigaimani S, Lau DH, Brooks AG, et al. Tranilast prevents hypertensive atrial electrical and structural remodeling independent of systolic blood pressure level: a comparative study with blood pressure lowering therapies. Circulation. 2014;130(Suppl 2):A18013.
   Google Scholar
• Tsou P-S, Haak AJ, Khanna D, et al. Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. Am J Physiol Physiol. 2014;307(1):C2–C13.
   Google Scholar
• Ogata T, Ueyama T, Isodono K, et al. MURC, a muscle-restricted coiled-coil protein that modulates the Rho/ROCK pathway, induces cardiac dysfunction and conduction disturbance. Mol Cell Biol. 2008;28(10):3424–3436.
   PubMed Web of Science ®Google Scholar
• Nakerakanti SS, Bujor AM, Trojanowska M. CCN2 is required for the TGF-β induced activation of Smad1 – Erk1/2 signaling network. Plos One. 2011;6(7):e21911.
   PubMed Web of Science ®Google Scholar
• Liu S, Shi-Wen X, Abraham DJ, et al. CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum. 2011;63(1):239–246.
   PubMed Web of Science ®Google Scholar
• Teekakirikul P, Eminaga S, Toka O, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest. 2010;120(10):3520–3529.
   PubMed Web of Science ®Google Scholar
• Ahmed MS, Gravning J, Martinov VN, et al. Mechanisms of novel cardioprotective functions of CCN2/CTGF in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circulatory Physiol. 2011;300(4):H1291–H1302.
   Google Scholar
• Hall-Glenn F, Lyons KM. Roles for CCN2 in normal physiological processes. CMLS. 2011;68(19):3209–3217.
   PubMed Web of Science ®Google Scholar
• Zhang D, Liu X, Chen X, et al. Role of the MAPKs/TGF-β1/TRAF6 signaling pathway in atrial fibrosis of patients with chronic atrial fibrillation and rheumatic mitral valve disease. Cardiology. 2014;129(4):216–223.
   PubMed Web of Science ®Google Scholar
• Adam O, Lavall D, Theobald K, et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol. 2010;55(5):469–480.
   PubMed Web of Science ®Google Scholar
• Thorin E, Clozel M. The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol. 2010;60:1–26.
   PubMedGoogle Scholar
• Shi-Wen X, Howat SL, Renzoni EA, et al. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem. 2004;279(22):23098–23103.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Suzuki K, Hara M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis. 1994;53(8):506–510.
   PubMed Web of Science ®Google Scholar
• Park S-H, Saleh D, Giaid A, et al. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med. 1997;156(2):600–608.
   PubMed Web of Science ®Google Scholar
• Jain R, Shaul PW, Borok Z, et al. Endothelin-1 induces alveolar epithelial–mesenchymal transition through endothelin type A receptor–mediated production of TGF-β1. Am J Respir Cell Mol Biol. 2007;37(1):38–47.
   PubMed Web of Science ®Google Scholar
• Kim KK, Chapman HA. Endothelin-1 as initiator of epithelial–mesenchymal transition. Am J Respir Cell Mol Biol. 2007;37(1):1–2.
   PubMed Web of Science ®Google Scholar
• Mayyas F, Niebauer M, Zurick A, et al. Association of left atrial endothelin-1 with atrial rhythm, size and fibrosis in patients with structural heart disease. Circ Arrhythm Electrophysiol. 2010;3(4):369–379.
   PubMed Web of Science ®Google Scholar
• Ai Z, Fischer A, Spray DC, et al. Wnt-1 regulation of connexin43 in cardiac myocytes. J Clin Investig. 2000;105(2):161–171.
   PubMed Web of Science ®Google Scholar
• Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44(6):670–675.
   PubMed Web of Science ®Google Scholar
• Lozano-Velasco E, Hernández-Torres F, Daimi H, et al. Pitx2 impairs calcium handling in a dose-dependent manner by modulating Wnt signalling. Cardiovasc Res. 2016;109(1):55–66.
   PubMed Web of Science ®Google Scholar
• Mayyas F, Alzoubi KH, van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol. 2013;168(6):5135–5142.
   PubMed Web of Science ®Google Scholar
• Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing–induced congestive heart failure. Circulation. 2001;104(21):2608–2614.
   PubMed Web of Science ®Google Scholar
• Sakabe M, Fujiki A, Nishida K, et al. Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin43 in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Pharmacol. 2004;43(6):851–859.
   PubMed Web of Science ®Google Scholar
• Shi Y, Li D, Tardif J-C, et al. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res. 2002;54(2):456–461.
   PubMed Web of Science ®Google Scholar
• Yang D, Yuan J, Liu G, et al. Angiotensin receptor blockers and statins could alleviate atrial fibrosis via regulating platelet-derived growth factor/Rac1 /nuclear factor-kappa B axis. Int J Med Sci. 2013;10(7):812–824.
   PubMed Web of Science ®Google Scholar
• Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360(16):1606–1617.
   PubMed Web of Science ®Google Scholar
• Du H, Fan J, Ling Z, et al. Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients. Hypertension. 2013;61(4):786–792.
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Maffioli P, et al. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. Clin Cardiol. 2012;35(6):359–364.
   PubMed Web of Science ®Google Scholar
• Murray KT, Rottman JN, Arbogast PG, et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 2004;1(6):669–675.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace. 2011;13(4):473–479.
   PubMed Web of Science ®Google Scholar
• Zhao D, Wang Z-M, Wang L-S. Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials. J Biomed Res. 2015;29(6):475–485.
   PubMed Web of Science ®Google Scholar
• Li TJ, Zang WD, Chen YL, et al. Renin-angiotensin system inhibitors for prevention of recurrent atrial fibrillation: a meta-analysis. Int J Clin Pract. 2013;67(6):536–543.
   PubMed Web of Science ®Google Scholar
• Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace. 2011;13(5):610–625.
   PubMed Web of Science ®Google Scholar
• Yi S-L, Liu X-J, Zhong J-Q, et al. Role of caveolin-1 in atrial fibrillation as an anti-fibrotic signaling molecule in human atrial fibroblasts. PLoS One. 2014;9(1):e85144.
   Google Scholar
• Davies L, Jin J, Shen W, et al. Mkk4 is a negative regulator of the transforming growth factor beta 1 signaling associated with atrial remodeling and arrhythmogenesis with age. J Am Heart Assoc: Cardiovasc Cerebrovasc Dis. 2014;3(2):e000340.
   Google Scholar
• Parikh A, Patel D, McTiernan CF, et al. Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts. Circ Res. 2013;113(3):313–321.
   PubMed Web of Science ®Google Scholar
• Lee KW, Everett TH, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 2006;114(16):1703–1712.
   PubMed Web of Science ®Google Scholar
• Behnes M, Hoffmann U, Lang S, et al. Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clin Res Cardiol. 2010;100(4):335–342.
   PubMed Web of Science ®Google Scholar
• Zheng W, Yan C, Wang X, et al. The TGFB1 functional polymorphism rs1800469 and susceptibility to atrial fibrillation in two Chinese Han populations. PLoS One. 2013;8(12):e83033.
   PubMed Web of Science ®Google Scholar
• Lau DH, Psaltis PJ, Carbone A, et al. Atrial protective effects of n-3 polyunsaturated fatty acids: a long-term study in ovine chronic heart failure. Heart Rhythm. 2011;8(4):575–582.
   PubMed Web of Science ®Google Scholar
• Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation. 2007;116(19):2101–2109.
   PubMed Web of Science ®Google Scholar
• Kumar S, Sutherland F, Stevenson I, et al. Effects of long-term omega-3 polyunsaturated fatty acid supplementation on paroxysmal atrial tachyarrhythmia burden in patients with implanted pacemakers: results from a prospective randomised study. Int J Cardiol. 2013;168(4):3812–3817.
   PubMed Web of Science ®Google Scholar
• Larsson SC, Wolk A. Fish, long-chain omega-3 polyunsaturated fatty acid intake and incidence of atrial fibrillation: a pooled analysis of two prospective studies. Clin Nutr. 2016. doi:10.1016/j.clnu.2016.01.019
   Google Scholar
• Ke L, Meijering RAM, Hoogstra-Berends F, et al. HSPB1, HSPB6, HSPB7 and HSPB8 protect against RhoA GTPase-induced remodeling in tachypaced atrial myocytes. PLoS One. 2011;6(6):e20395.
   Google Scholar
• Sapra G, Tham YK, Cemerlang N, et al. The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice. Nat Commun. 2014;5:5705.
   Web of Science ®Google Scholar
• Harada M, Luo X, Qi XY, et al. Transient receptor potential canonical-3 channel–dependent fibroblast regulation in atrial fibrillation. Circulation. 2012;126(17):2051–2064.
   PubMed Web of Science ®Google Scholar
• Du J, Xie J, Zhang Z, et al. TRPM7-mediated Ca(2+) signals confer fibrogenesis in human atrial fibrillation. Circ Res. 2010;106(5):992–1003.
   PubMed Web of Science ®Google Scholar
• Qi XY, Huang H, Ordog B, et al. Fibroblast inward-rectifier potassium current upregulation in profibrillatory atrial remodeling. Circ Res. 2015;116(5):836–845.
   PubMed Web of Science ®Google Scholar
• Clauss S, Sinner MF, Kaab S, et al. The role of MicroRNAs in antiarrhythmic therapy for atrial fibrillation. Arrhythm Electrophysiol Rev. 2015;4(3):146–155.
   PubMedGoogle Scholar
• Dawson K, Wakili R, Ordog B, et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation. 2013;127(14):1466-75, 1475e1-28.
   PubMed Web of Science ®Google Scholar
• Ishida W, Mori Y, Lakos G, et al. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol. 2006;126(8):1733–1744.
   PubMed Web of Science ®Google Scholar
• Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-β1-induced extracellular matrix expression. Mol Pharmacol. 2006;69(2):597–607.
   PubMed Web of Science ®Google Scholar
• Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976–985.
   PubMed Web of Science ®Google Scholar
• Ten Freyhaus H, Dumitrescu D, Berghausen E, et al. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs. 2012;21(1):119–134.
   PubMed Web of Science ®Google Scholar
• Skhirtladze C, Distler O, Dees C, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 2008;58(5):1475–1484.
   PubMed Web of Science ®Google Scholar
• Lau DH, Volders PGA, Kohl P, et al. Opportunities and challenges of current electrophysiology research: a plea to establish ‘translational electrophysiology’ curricula. Europace. 2015;17(5):825–833.
   PubMed Web of Science ®Google Scholar
• Lau DH, Schotten U, Mahajan R, et al. Novel mechanisms in the pathogenesis of atrial fibrillation: practical applications. Eur Heart J. 2016;37(20):1573–1581.
   PubMed Web of Science ®Google Scholar
• Teh AW, Kistler PM, Lee G, et al. Long-term effects of catheter ablation for lone atrial fibrillation: progressive atrial electroanatomic substrate remodeling despite successful ablation. Heart Rhythm. 2012;9(4):473–480.
   PubMed Web of Science ®Google Scholar
• Chao TF, Ambrose K, Tsao HM, et al. Relationship between the CHADS(2) score and risk of very late recurrences after catheter ablation of paroxysmal atrial fibrillation. Heart Rhythm. 2012;9(8):1185–1191.
   PubMed Web of Science ®Google Scholar
• Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114(9):1453–1468.
   PubMed Web of Science ®Google Scholar
• Lau DH, Schotten U, Mahajan R, et al. Novel mechanisms in the pathogenesis of atrial fibrillation: practical applications. Eur Heart J. 2016;37(20):1573–1578.
   Web of Science ®Google Scholar
• Nattel S, Guasch E, Savelieva I, et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J. 2014;35(22):1448–1456.
   PubMed Web of Science ®Google Scholar
• Gallagher C, Hendriks JML, Mahajan R, et al. Lifestyle management to prevent and treat atrial fibrillation. Expert Rev Cardiovasc Ther. 2016;14(7):799–809.
   PubMed Web of Science ®Google Scholar
• Mahajan R, Brooks A, Manavis J, et al. Atrial fibrillation and obesity: impact of weight reduction on the atrial substrate. Heart, Lung and Circulation. 2013;22:S1–S2.
   Google Scholar
• Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050–2060.
   PubMed Web of Science ®Google Scholar
• Pathak RK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159–2169.
   PubMed Web of Science ®Google Scholar
• Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation – the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64(21):2222–2231.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016. DOI:10.1093/eurheartj/ehw2102016
   Google Scholar